POTENTIAL MERGER (Details Textual) - Subsequent Event [Member] - Innovate Biopharmaceuticals, Inc. [Member] $ in Millions |
Jul. 03, 2017
USD ($)
|
|---|---|
| Business Acquisition, Transaction Costs | $ 6 |
| Business Acquisition, Pro Forma Information, Description | As a result, current securityholders of the Company would collectively own approximately 9% and Innovate securityholders would collectively own approximately 91% of the combined company on a pro-forma basis, subject to adjustment based on the Companys net cash balance and the relative capitalization of the two companies at closing, as described more fully in the Merger Agreement. |
| Innovates Business [Member] | |
| Business Acquisition, Transaction Costs | $ 60 |